Thursday, March 31, 2011

Stocks In Focus: DNDN, GOOG, BRK-B, MAKO

Shares of Dendreon (NASDAQ: DNDN) rallied as much as 4% in Thursday's pre-market trading after the U.S. Centers for Medicare and Medicaid Services said it's leaning toward backing coverage of the company's Provenge treatment for prostate cancer. The $93,000 drug regimen is reasonable and necessary for men with advanced, castrate- resistant prostate tumors who have minimal or no symptoms of the disease, the Centers for Medicare & Medicaid Services said.

In a blog post, Microsoft Corp. (NASDAQ: MSFT) said late Wednesday that it is filing a formal complaint against Google Inc. (NASDAQ: GOOG) with the European Commission as part of the commission’s investigation into Google’s dominance in online search.

Berkshire Hathaway (NYSE: BRK-B) announced that David Sokol resigned from the firm after it came to light that he had bought millions of dollars of Lubrizol Corp. (NYSE: LZ)  shares before urging Warren Buffett to buy the company.

Shares of MAKO Surgical Corp. (NASDAQ: MAKO) jumped more than 6% after the company announced receipt of a binding commitment for the establishment of eleven new MAKOplasty sites from Health Management Associates, Inc. (NYSE: HMA) , a premier operator of acute care hospitals primarily in the southeast and southwest areas of non-urban America. It is expected that these MAKOplasty sites will be established over the course of 2011.

Full Disclosure: None.
Related Posts with Thumbnails

Wikinvest Wire